David J Panka

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
  2. pmc An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Melanoma Res 20:401-7. 2010
  3. pmc Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells
    David J Panka
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 12:17. 2013
  4. pmc Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
    Qingjun Liu
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 10:115. 2011
  5. ncbi request reprint GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Biol Chem 283:726-32. 2008
  6. ncbi request reprint Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2371s-2375s. 2006
  7. doi request reprint Assaying for BRAF V600E in tissue and blood in melanoma
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Methods Mol Biol 1102:117-36. 2014
  8. ncbi request reprint The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Cancer Res 66:1611-9. 2006

Detail Information

Publications8

  1. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
    ....
  2. pmc An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Melanoma Res 20:401-7. 2010
    ..Using this protocol, mutant Braf can be detected in RNA from mixed populations with as few as 0.1% Braf(V600E) mutant cells...
  3. pmc Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells
    David J Panka
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 12:17. 2013
    ..The studies reported herein were undertaken to determine if the angiostatic function of p53 could be exploited as an adjunct to VEGF-targeted therapy in the treatment of renal cell carcinoma (RCC)...
  4. pmc Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma
    Qingjun Liu
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mol Cancer 10:115. 2011
    ..In this report, we describe the results of studies exploring the effects of GSK-3β on the cytotoxicity and antitumor activity of sorafenib combined with the HDM2 antagonist MI-319...
  5. ncbi request reprint GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Biol Chem 283:726-32. 2008
    ..These data provide a strong rationale for the use of GSK-3beta inhibitors as adjuncts to sorafenib treatment and suggest that preservation of Noxa may contribute to their efficacy...
  6. ncbi request reprint Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2371s-2375s. 2006
    ....
  7. doi request reprint Assaying for BRAF V600E in tissue and blood in melanoma
    David J Panka
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Methods Mol Biol 1102:117-36. 2014
    ..Using this protocol, mutant BRAF can be detected in RNA from mixed populations with as few as 0.1 % BRAF(V600E) mutant containing cells...
  8. ncbi request reprint The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Cancer Res 66:1611-9. 2006
    ..These data indicate that in sensitive cell lines, BAY 43-9006-induced apoptosis is independent of Bad dephosphorylation and caspase activation and largely mediated through the nuclear translocation of AIF...